{"organizations": [], "uuid": "d7c70fffe5fbce8f5ba3848d283716947845ae17", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180222.html", "section_title": "Archive News &amp; Video for Thursday, 22 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/sobi-results/update-1-sobi-q4-tops-forecast-but-2018-outlook-below-market-expectations-idUSL8N1QC1LW", "country": "US", "domain_rank": 408, "title": "UPDATE 1-‍Sobi Q4 tops forecast but 2018 outlook below market expectations​", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-22T16:11:00.000+02:00", "replies_count": 0, "uuid": "d7c70fffe5fbce8f5ba3848d283716947845ae17"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/sobi-results/update-1-sobi-q4-tops-forecast-but-2018-outlook-below-market-expectations-idUSL8N1QC1LW", "ord_in_thread": 0, "title": "UPDATE 1-‍Sobi Q4 tops forecast but 2018 outlook below market expectations​", "locations": [], "entities": {"persons": [{"name": "orphan biovitr", "sentiment": "negative"}, {"name": "sobi", "sentiment": "none"}, {"name": "guido oelkers", "sentiment": "none"}, {"name": "bioverativ", "sentiment": "none"}], "locations": [{"name": "sobi", "sentiment": "none"}, {"name": "europe", "sentiment": "none"}, {"name": "elocta", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "sobi", "sentiment": "none"}, {"name": "elocta", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "(Adds details, background, shares)\nFeb 22 (Reuters) - Rare-disease drug maker Swedish Orphan Biovitrum (Sobi) reported on Thursday a bigger fourth-quarter profit jump than expected but guided for slightly slower profit growth in 2018 than estimated by analysts.\n* Sobi makes haemophilia, inflammation and genetic and metabolic disease drugs, with roughly half of sales in Europe\n* Q4 operating profit before amortisation (EBITA) up 195 pct yr/yr to 619 mln SEK ($76.1 mln) vs Reuters’ analyst poll mean forecast of 565 mln, helped by strong growth across the portfolio, for new haemophilia drugs in particular\n* In the full year, EBITA and sales landed just above Sobi’s forecast range\n* “Our Haemophilia franchise continued to grow rapidly and our strong quarter-on-quarter growth shows that we delivered consistently on our launch strategy for Elocta and Alprolix,” said Guido Oelkers, who joined Sobi as new CEO in May last year\n* Q4 sales of key haemophilia drugs Elocta and Alprolix, which are partly sold by partner Bioverativ, were 540 mln and 131 mln SEK, respectively, above forecast\n* Sobi gave a full-year 2018 outlook for EBITA of 2.50-2.70 bln SEK on sales of 7.50-7.70 bln, with a ‍gross margin of at least 70 pct. Analysts’ mean forecasts ahead of the news were for FY 2018 EBITA of 2.83 bln and sales of ​7.90 bln\n* Sobi shares drop 1.6 pct in early trading on Thursday, underperforming the wider Stockholm market\n* Shares in Sobi, whose rivals include Roche, Novo Nordisk and Shire, were up 17 pct YTD at Wednesday’s close\n* Most of the YTD gain for the stock came on Jan. 22, after French healthcare group Sanofi said ith had agreed to buy Bioverativ for $11.6 bln\nSource text for Eikon: Further company coverage: ($1 = 8.1355 Swedish crowns) (Reporting By Anna Ringstrom; editing by Johannes Hellstrom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-22T16:11:00.000+02:00", "crawled": "2018-02-23T15:59:18.025+02:00", "highlightTitle": ""}